Dr. Lary Robinson is one of the nation’s leading surgeons, with a specialty in treating mesothelioma and advanced lung cancer.
Dr. Lary Robinson has had a long and varied career in medicine, with a speciality in treating mesothelioma and advanced lung cancer patients. In addition to his training in medical school and through his fellowships and residencies, Dr. Robinson also learned a lot as he served as a flight surgeon for the United States Air Force. He currently serves as the director in the Division of Cardiovascular and Thoracic Surgery at the H. Lee Moffitt Cancer Center & Research Institute, with affiliations at the University of South Florida as well as several hospitals.
Dr. Robinson is considered an expert surgeon, with board certifications in surgery, surgical critical care, and thoracic and cardiac surgery. Before serving in his current director role, Dr. Robinson has worked to impart his skill and expertise on other budding surgeons. He has taught as an associate professor of surgery and pharmacology at the University of Nebraska, as well as serving as their medical center’s Clinical Director of the Clinical Perfusion Science Education Program.
Through his time living and practicing in Florida, Dr. Robinson has also held multiple positions before becoming director. He taught as a professor of surgery at Tampa-based University of South Florida College of Medicine. He also served as the principle thoracic surgical oncologist at his current cancer center. His clinical expertise and compassionate care has helped numerous patients, as well as students as they look to begin their own medical careers.
Professional Interests and Clinical Research
Through his lengthy career, Dr. Robinson has been involved in much clinical research, having published well over 125 medical studies, articles and books. His professional interests are varied, with a main focus on thoracic and cardiovascular surgery techniques. Though he is interested in and treats different conditions, he does specialize in lung conditions in particular.
In addition to the many clinical trials he’s led or collaborated on, Dr. Robinson has also been directly involved in 8 clinical cancer research programs relating to lung cancer and mesothelioma. His efforts have led to treatment advancements, as well as helped better understand these conditions overall.
Most recently, Dr. Robinson is collaborating on a phase II clinical trial testing the safety and efficacy of a transarterial chemoperfusion treatment of three chemotherapy drugs for pleural mesothelioma. The study is further testing a combination of chemotherapy drugs cisplatin, methotrexate and gemcitabine in patients who have pleural mesothelioma that can not be treated with surgery and have not seen success with prior chemotherapy.
Localized pleural mesothelioma. The clinical spectrum. Chest. November 1994; 106(5): 1611-1615. doi:10.1378/chest.106.5.1611.
Molecular evidence of viral DNA in non-small cell lung cancer and non-neoplastic lung. British Journal of Cancer. August 2016; 115(4):497-504. doi: 10.1038/bjc.2016.213.
“Keeling” Syndrome — A Late Complication of Pneumonectomy. The New England Journal of Medicine. October 1996; 335:1074. doi: 10.1056/NEJM199610033351419.
Using “Rebar” to Stabilize Rigid Chest Wall Reconstruction. The Journal of Thoracic and Cardiovascular Surgery. April 2016; 64(3):266-9. doi: 10.1055/s-0034-1396933.
Dr. Robinson has been recognized on many occasions throughout his career thus far. Castle Connelly has named Dr. Robinson as one of “America’s Top Doctors” and “America’s Top Doctors for Cancer” annually since the mid-2000s. He has also received other awards recognizing his expertise and contributions to the medical field.
Physician of the Year Award 2016 – H. Lee Moffitt Cancer Center
Distinguished Service Award – Clinical Perfusion Science Faculty
Air Force Commendation Medal for Meritorious Service – U.S. Air Force